Objective To observe the clinical effect of eye drops of 0.1%olopatadine hydrochloride(patanol) and 0.05%FKS06 (tacrolimus) for treating severe vernal keratoconjunctivitis in children.Design Prospective case siries.Participants 62 cases(104 eyes) of severe vernal keratoconjunctivitis aged 3-14 years old.Methods We observed the symptoms and signs of severe vernal keratoconjunctivitis before and after the treatment of 0.1%olopatadine hydrochloride and 0.05%FKS06.We examined regularly the blood,liver and kidney functions for all patients during treatment.Main Outcome Measures Symptoms and signs.Results Following by 3- 34months,all patients were much better in different degree at 1 week than that before.The papillae were decreased and almost disappeared gradually at 1 month.The corneal lesions were cured rapidly in less than 2 weeks.2 cases(3.2%) complained a little disconfort just at the beginning.38 cases(61.3%) recurred from 2 weeks to 8 months after stopping the eye drops,and were controlled rapidly after reusing the eye drops.The blood routine and the biochemical functions of all patients were normal during treatment.Conclusions 0.1% olopatadine hydrochloride and 0.05%FKS06 have remarkable effects for alleviating symptoms and signs of severe vernal keratoconjunctivitis. The patients are comfortable and content with the treatment,and side effects are very few.

Dental Implantation, Endosseous ; methods ; Dental Implants ; Dental Restoration Failure ; Denture, Complete, Immediate ; Humans ; Jaw, Edentulous ; surgery

OBJECTIVE To monitor the Enterobacter cloacae resistance in our hospital patients.METHODS Disk susceptibility tests were performed for detection of E.cloacae resistance to 10 antibiotics,Detection of(extended)-spectrum ?-lactamases and AmpC ?-lactamase was conducted by three-dimensional extract test.RESULTS Seventy four strains of E.cloacae were isolated from our hospital patients,its had high resistant rate to 9 antibiotics(from(40.5%) to 91.8%),Among 74 strains of E.cloacae,10 isolates(13.5%) were considered as AmpC enzyme producing,31 strains(41.89%) were ESBLs-producing,6 strains(8.1%) were producing both of them.Total detection of AmpC(?-lactamase),or the production of ESBLs,or both of them were 47 strains(63.5%).Only imipenem was effective for all E.cloacae.CONCLUSIONS For the serious infection induced by E.cloacae producing AmpC ?-lactamase or(ESBLs),imipenem is first choice of treatment.

Objective To evaluate the ethical management status quo of Capital Medical Research Fund in 2007.Methods Cross-sectional study was applied to analyze the ethics management and ethics self-evaluation in applications.Results There were 652 applications,covering with 14 districts and 2 counties in Beijing,from 128 Hospitals.Applicants have some knowledge of the ethical issues in clinical research accounted for 88.7％ ; informed consent of subjects considered in 72.5％ ;the potential risk and protection involved in application accounted for 62.0％; personal privacy protection of subject accounted for 49.4％.Unfortunately,the benefit vs risk assessment was only involved in 28.7％ applications.Applicants from general hospitals had more ethical issue knowledge (90.2％) than those from community hospitals (84.6％).Applicants from university hospitals had more ethical issue knowledge (93.9％) than those from military hospitals (80.2％).Applicants aged 55 0r over had less ethical issue knowledge (70.0％) than other applicants (89.2％).The applicants to study on descriptive research and etiological research had less ethical issue knowledge than others.578 applications filled out the approval from ethics committee or research management department.62.6％ of the written were acceptable.Conclusion The applicants for clinical research had preliminary understanding for ethical issues in Beijing in 2007.Hospital ethics committees or research management departments had conducted clinical research ethical review applications for funds management.It has taken place the external conditions to carry out the ethical management in clinical research fund management.

OBJECTIVE: To investigate the influences of staphylococcus aureus in planktonic and biofilm forms on the expression of lysozyme, SLPI and gp340 in the human sinonasal explant model. METHOD: Mucosa samples from ethmoid sinus were collected from ten patients of cerebrospinal fluid leak and were cultured with and without S. aureus biofilms and planktonic cells. After the infection, the explant model was confirmed by CLSM, and the secretion of lysozyme, SLPI and gp340 was detected by enzyme-linked immunosorbent assay (ELISA) at 8, 16, and 24 h after S. aureus challenge. Expressions of lysozyme, SLPI and gp340 in mRNA and protein levels after 24 h S. aureus challenge were detected using RT-PCR, immunohistochemistry and Western bolt assay respectively. RESULT: The secretion of lysozyme, SLPI and gp340 in the explant model was observed with a trend to increase in a time-dependent manner. At 8 and 16 h after S. aureus challenge, the secretion of lysozyme, SLPI and gp340 in biofilms group was significantly higher than these in planktonic cells group and control group (P<0. 05). S. aureus biofilms enhanced the mRNA expressions of lysozyme, SLPI and gp340 significantly compared with planktonic cells and controls, and the mRNA expressions in the explant model challenged by planktonic cells were significantly higher than controls (P < 0.05). Although the Western bolt assay showed no differences between the lysozyme expression in the planktonic cells group and control group (P > 0.05), the biofilms enhanced the expressions of lysozyme, SLPI and gp340 significantly compared with planktonic cells and controls (P < 0.05). CONCLUSION S. aureus biofilm induced the expressions of lysozyme, SLPI and gp340 to a higher level than planktonic cells, indicating that S. aureus biofilm was an influencing factor on the innate immune system.
Biofilms ; Enzyme-Linked Immunosorbent Assay ; Ethmoid Sinus ; metabolism ; microbiology ; Humans ; Immunity, Innate ; Muramidase ; metabolism ; RNA, Messenger ; metabolism ; Receptors, Cell Surface ; metabolism ; Secretory Leukocyte Peptidase Inhibitor ; metabolism ; Staphylococcal Infections ; metabolism ; Tissue Culture Techniques

0.05).Conclusions:Combined anchorage can provide maximum anchorage compared with traditional face bow and was accepted easily by patients.

Objective To explore the prevalence of nonalcoholic fatty liver disease(NAFLD)in patients with polycystic ovary syndrome(PCOS).MethodsA case-control study employing 60 non pregnant patients with PCOS and 60 non-pregnant patients without PCOS as control was conducted to compare the prevalence of NAFLD.Resuits The aminotransferase(ALT),fasting insulin and homeostasis model assessment of insulin resistance(HOMA-IR)levels were(29±15)U/L,(19±12)mU/L and 0.47±0.29 in PCOS group,which were significantly higher(P＜0.05)than corresponding parameters in control group[(15±13)U/L,(11±8)mU/L and 0.31±0.21)].The occurrence of insulin resistance and NAFLD was 63％(38/60)and 42％(25/60),higher than those in control group[35％(21/60)and 20％(12/60),P＜0.05].The increment of ALT was 40％(24/60)in PCOS group,higher than that of 3％(2/60)in control group(P＜0.01).Compared with patients witIlout NAFLD,patients with NAFLD had significantly increased body mass index(P＜0.01),waist-hip ratio,AIJT,C-reaction protein,fasting insulin,insulin and HOMA-IR levels 2 hours after oral glucose tolerance test(P＜0.05).Conchsion The increased prevalence of NAFLD in PCOS patients suggests an association between these two conditions and the necessity of hepatic screening among PCOS patients for potential NAFLD.

BACKGROUND:Stem cel therapy has been used for prevention and treatment of degenerative disc disease. Considering the special microenvironment in the intervertebral disc, the survival rate and differentiation ability of transplanted cels are decreased, which may lead to the poor efficacy of stem cel therapy. How to improve the survival ability and therapeutic effect of the transplanted cels is the focus of stem cel therapy for degenerative disc disease.
OBJECTIVE: To investigate the effects of cobalt chloride combined with hypertonic solution pretreatment on bone marrow mesenchymal stem cels that wil be transplanted for treatment of degenerative disc disease.
METHODS:(1)In vitro cel experiment: bone marrow mesenchymal stem cels were divided into three groups and subjected to normal culture medium (normal control group), 1% hypertonic mother solution (hypertonic group), 100 μmol/L cobalt chloride (hypoxia group), or 1% hypertonic mother solution plus 100 μmol/L cobalt chloride (combined group) for 1 week. Then, 2% hypertonic solution and 200 μmol/L cobalt chloride cobalt chloride were used to simulate the anaerobic and hypertonic environment intervenes in pretreated and untreated bone marrow mesenchymal stem cels for 24 hours. After that, RT-PCR was used to detect the expression of caspase-3 for apoptosis evaluation. (2)In vivo animal experiment: Sprague-Dawley rats were divided into model, cel transplantation and hypertonic plus hypoxic groups. Rat models of intervertebral disc degeneration were made in these three groups. After modeling, rats in these three groups were given no treatment, bone marrow mesenchymal stem cel transplantation or transplantation of bone marrow mesenchymal stem cels which were subjected to hypertonic and hypoxia pretreatments into the intervertebral disc. Two weeks later, immunohistochemistry and RT-PCR methods were used to detect cel distribution and related gene expression, respectively, thereby to evaluate the therapeutic effect of stem cels.
RESULTS AND CONCLUSION: (1)In vitro cel experiment: caspase-3 mRNA expression was significantly reduced in pretreated bone marrow mesenchymal stem cels compared with the untreated cels (P < 0.05). (2)In vivo animal experiment: compared with the control group, the caspase-3 and interleukin-1β in the intervertebral disc and a number of degenerative indexes were decreased in the cel transplantation. Compared with the cel transplantation group, these indicators had better outcomes in the hypertonic plus hypoxic group (P < 0.05). These findings indicate that bone marrow mesenchymal stem cels have therapeutic potential for degenerative disc disease, and have better adaptability and transplantation effects by hypertonic and hypoxia pretreatments.

Objective To investigate the association between PARK16 gene polymorphism and Parkinson's disease(PD)susceptibility in Chinese Han population.and to analyze its single-nucleotide polymorphism(SNP)genotypes,frequencies and odds ratios(OR)of different genotypes.Methods The association between two SNP loci in PARK16 gene(Rs947211,Rs823128)and PD susceptibility was investigated by TaqMan quantitative polymerase chain reaction(PCR)in 226 PD patients and 362 healthy controls.Allele and genotype frequencies were calculated by the Chi-square test,and the clinical data were also analyzed.Results Three genotypes of Rs947211(GG,AG and AA)account for 34.1%(77/226),46.0%(104/226),19.9%(45/226)in the PD group,and 23.8%(86/362),53.0%(192/362),23.2%(84/362)in the control group,respectively.There was significant difference between two groups (P<0.05).Setting the GG genotype as the reference,OR values of AG and AA genotype were 0.57(95%CI0.38-0.85,P=0.006)and 0.55(95%CI 0.34-0.85,P=0.015),while the OR value for exposure to the A allele(AA+AG)was 0.56(95%CI0.38-0.82,P=0.003).Genotypes of Iate-onset PD were also significantly different from the controls(OR valne of AG=0.46,95%CI 0.27-0.78,P=0.004:OR value of AA=0.35.95%CI 0.18-0.68,P=0.002).And there was no diffefence in clinical features among the 3 genotypes. The frequency of Rs823128, another locus, in PD group was not significantly different from the control group( AA genotype as the reference, OR value of AG was 1. 12, 95% CI 0. 75-1.68, P = 0.568; OR value of GG was 0.99, 95% CI 0.35-2.76, P = 0.994). Conclusion Polymorphism of PARK 16 locus Rs947211 is associated with PD patients in Chinese Han population.

Objective: To explore current status of antithrombotic therapy in patients with non-valvular atrial ifbrillation (NVAF) at Macau area of china via clinical data analysis.
Methods: A total of 472 NVAF patients treated in Centro Hospitalar Conde de S?o Januário (CHCSJ) from 2014-01 to 2041-12 were enrolled. The patients were at the age of (73.0±10.9) years including 197 (41.7%) female and 244 (51.7%)≥75 years. The baseline condition, clinical characteristics and antithrombotic therapy were analyzed; relevant scores were calculated, CHA2DS2-VASc score≥2 was deifned as high risk of stroke and HAS-BLED score≥3 was deifned as high risk of bleeding.
Results: The average CHA2DS2-VASc score was (3.4±1.8) and 389/472 (82.4%) patients with CHA2DS2-VASc scor≥2; the mean HAS-BLED score was (1.96±1.03) and 132 (28.0%) patients with HAS-BLED score≥3. There were 184 (38.9%) patients received antiplatelet therapy, 101 (21.4%) received warfarin, 156 (33.1%) received new oral anticoagulant drug and 22 patients taken both antiplatelet and anticoagulant treatments simultaneously; 53 (11.2%) patients had no antithrombotic therapy. The patients with high risk of stroke had the higher rate of anticoagulant therapy (215/472, 55.3%) and the application rate of new anticoagulant drug was higher than warfarin.
Conclusion: NVAF patients had the higher risk of stroke as more than 80% with CHA2DS2-VASc score≥2 and most patients received anticoagulant therapy in Macau area. The application rate of new anticoagulant drug was higher than warfarin.